These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31078573)

  • 1. Changes in neuronal activity in rat primary cortical cultures induced by illicit drugs and new psychoactive substances (NPS) following prolonged exposure and washout to mimic human exposure scenarios.
    Zwartsen A; Hondebrink L; Westerink RH
    Neurotoxicology; 2019 Sep; 74():28-39. PubMed ID: 31078573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotoxicity screening of new psychoactive substances (NPS): Effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA).
    Zwartsen A; Hondebrink L; Westerink RH
    Neurotoxicology; 2018 May; 66():87-97. PubMed ID: 29572046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hazard Characterization of Synthetic Cathinones Using Viability, Monoamine Reuptake, and Neuronal Activity Assays.
    Zwartsen A; Olijhoek ME; Westerink RHS; Hondebrink L
    Front Neurosci; 2020; 14():9. PubMed ID: 32063828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?
    Hondebrink L; Zwartsen A; Westerink RHS
    Pharmacol Ther; 2018 Feb; 182():193-224. PubMed ID: 29097307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxicity screening of (illicit) drugs using novel methods for analysis of microelectrode array (MEA) recordings.
    Hondebrink L; Verboven AHA; Drega WS; Schmeink S; de Groot MWGDM; van Kleef RGDM; Wijnolts FMJ; de Groot A; Meulenbelt J; Westerink RHS
    Neurotoxicology; 2016 Jul; 55():1-9. PubMed ID: 27149913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermia exacerbates the acute effects of psychoactive substances on neuronal activity measured using microelectrode arrays (MEAs) in rat primary cortical cultures in vitro.
    Zwartsen A; Hondebrink L; de Lange DW; Westerink RHS
    Toxicol Appl Pharmacol; 2020 Apr; 397():115015. PubMed ID: 32320794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay.
    Zwartsen A; Verboven AHA; van Kleef RGDM; Wijnolts FMJ; Westerink RHS; Hondebrink L
    Toxicol In Vitro; 2017 Dec; 45(Pt 1):60-71. PubMed ID: 28506818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bath salts and synthetic cathinones: an emerging designer drug phenomenon.
    German CL; Fleckenstein AE; Hanson GR
    Life Sci; 2014 Feb; 97(1):2-8. PubMed ID: 23911668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designer psychostimulants: pharmacology and differences.
    Iversen L; White M; Treble R
    Neuropharmacology; 2014 Dec; 87():59-65. PubMed ID: 24456744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychoactive 'bath salts': compounds, mechanisms, and toxicities.
    Lehner KR; Baumann MH
    Neuropsychopharmacology; 2013 Jan; 38(1):243-4. PubMed ID: 23147485
    [No Abstract]   [Full Text] [Related]  

  • 12. 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online.
    Coppola M; Mondola R
    Toxicol Lett; 2012 Jan; 208(1):12-5. PubMed ID: 22008731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M
    Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Ca
    Steele TWE; Eltit JM
    Psychopharmacology (Berl); 2019 Mar; 236(3):973-988. PubMed ID: 30448989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic Activity of Pyrovalerone Derivatives, an Emerging Group of Psychostimulant Designer Cathinones.
    Wojcieszak J; Andrzejczak D; Woldan-Tambor A; Zawilska JB
    Neurotox Res; 2016 Aug; 30(2):239-50. PubMed ID: 27295059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic cathinones: an evolving class of new psychoactive substances.
    Gonçalves JL; Alves VL; Aguiar J; Teixeira HM; Câmara JS
    Crit Rev Toxicol; 2019 Aug; 49(7):549-566. PubMed ID: 31747318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Psychoactive Substances: A Matter of Time.
    Pantano F; Graziano S; Pacifici R; Busardò FP; Pichini S
    Curr Neuropharmacol; 2019; 17(9):818-822. PubMed ID: 31577198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Illicit bath salts: not for bathing.
    Kyle PB; Iverson RB; Gajagowni RG; Spencer L
    J Miss State Med Assoc; 2011 Dec; 52(12):375-7. PubMed ID: 22329114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combined approach using transporter-flux assays and mass spectrometry to examine psychostimulant street drugs of unknown content.
    Rosenauer R; Luf A; Holy M; Freissmuth M; Schmid R; Sitte HH
    ACS Chem Neurosci; 2013 Jan; 4(1):182-90. PubMed ID: 23336057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland.
    Adamowicz P; Gieroń J; Gil D; Lechowicz W; Skulska A; Tokarczyk B
    Drug Test Anal; 2016 Jan; 8(1):63-70. PubMed ID: 26666629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.